Published in Cancer Weekly, September 11th, 2001
Duke University researchers in North Carolina, joined by colleagues at SRI International in Menlo Park, California, have performed rodent model experiments suggesting BTO-956 is a potent angiogenesis inhibitor. The drug has already been shown to affect human breast and ovarian cancer tumor growth in murine model studies.
In a first phase of the new experiments, Siqing Shan and colleagues, Duke University, Durham, implanted pellets containing the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.